The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Launched by NOVO NORDISK A/S · Jun 18, 2008
Trial Information
Current as of October 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes
- • Treatment with metformin alone for at least three months
- • HbA1c (glycosylated haemoglobin A1c) 7.5-10.0% (both inclusive)
- • Body Mass Index (BMI) less than or equal to 45.0
- Exclusion Criteria:
- • Previous treatment with insulin, glucagon like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors
- • Treatment with anti-diabetic drugs other than metformin within the last three months
- • Any serious medical condition
- • Females who are pregnant, have the intention of becoming pregnant or are breastfeeding
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Minneapolis, Minnesota, United States
San Antonio, Texas, United States
Huntington Beach, California, United States
Hyattsville, Maryland, United States
Berlin, New Jersey, United States
La Rochelle Cedex, France
Dormagen, Germany
Herrenberg, Germany
Völklingen, Germany
Apeldoorn, Netherlands
Zoetermeer, Netherlands
Abergavenny, United Kingdom
Ayr, United Kingdom
Sheffield, United Kingdom
Athens, Georgia, United States
Newport News, Virginia, United States
Narbonne, France
Venissieux, France
Ocala, Florida, United States
Boise, Idaho, United States
Dayton, Ohio, United States
Arlington, Texas, United States
Ogden, Utah, United States
Milwaukee, Wisconsin, United States
Orange, California, United States
Norristown, Pennsylvania, United States
Dallas, Texas, United States
Manati, Puerto Rico
Poway, California, United States
Messina, Italy
Roma, Italy
Roelofarendsveen, Netherlands
Getafe, Spain
Mentor, Ohio, United States
Richmond, Virginia, United States
Rio Piedras, Puerto Rico
Las Vegas, Nevada, United States
Pavia, Italy
Barcelona, Spain
Rennes, France
Hengelo, Netherlands
Bratislava, Slovakia
Schönebeck, Germany
Lucca, Italy
Hospitalet De Llobregat, Spain
Salford, United Kingdom
Dublin, Ireland
Aberdeen, United Kingdom
Birmingham, United Kingdom
Edinburgh, United Kingdom
Leicester, United Kingdom
Liverpool, United Kingdom
Nottingham, United Kingdom
Swansea, United Kingdom
Oviedo, Spain
La Roche Sur Yon Cedex 9, France
Aldershot, United Kingdom
Coventry, United Kingdom
Escondido, California, United States
Walnut Creek, California, United States
Jacksonville, Florida, United States
St. Cloud, Florida, United States
Shawnee Mission, Kansas, United States
St. Peters, Missouri, United States
Northport, New York, United States
Houston, Texas, United States
Ljubljana, Slovenia
Slavonski Brod, Croatia
Saint Mandé, France
Timisoara, Romania
Bad Lauterberg, Germany
Groningen, Netherlands
Málaga, Spain
Oxford, United Kingdom
Fresno, California, United States
Honolulu, Hawaii, United States
Montreal, Quebec, Canada
Edgbaston, Birmingham, United Kingdom
Belgrade, Former Serbia And Montenegro
Nis, Former Serbia And Montenegro
Catania, Italy
Siena, Italy
Almere, Netherlands
Zevenaar, Netherlands
Nitra, Slovakia
Long Beach, California, United States
Cincinnati, Ohio, United States
Ottawa, Ontario, Canada
Wangen, Germany
Palma De Mallorca, Spain
Strasbourg, France
Chicago, Illinois, United States
Kingsport, Tennessee, United States
St. George, Utah, United States
Northridge, California, United States
Panama City, Florida, United States
Dunwoody, Georgia, United States
Altoona, Pennsylvania, United States
Hurst, Texas, United States
Limoges, France
Alzira, Spain
Rosedale, New York, United States
Birmingham, Alabama, United States
Bochum, Germany
Frankfurt, Germany
Marburg, Germany
Dublin 9, Ireland
Novo Mesto, Slovenia
Puerto Del Rosario, Spain
Stadskanaal, Netherlands
Riesa, Germany
Trujillo Alto, Puerto Rico
Denver, Colorado, United States
Crystal River, Florida, United States
Miami, Florida, United States
Lithia Springs, Georgia, United States
Metairie, Louisiana, United States
Cleveland, Mississippi, United States
Pinehurst, North Carolina, United States
Tabor City, North Carolina, United States
Columbus, Ohio, United States
Cuyahoga Falls, Ohio, United States
Eugene, Oregon, United States
New Braunfels, Texas, United States
Sugar Land, Texas, United States
South Burlington, Vermont, United States
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
London, Ontario, Canada
Newmarket, Ontario, Canada
Toronto, Ontario, Canada
Hamilton, Canada
Karlovac, Croatia
Sisak, Croatia
Kassel, Germany
Ulm, Germany
Olbia, Italy
Palermo, Italy
Trieste, Italy
Beek, Netherlands
Leiden, Netherlands
Caquas, Puerto Rico
Guaynabo, Puerto Rico
Oradea, Bihor, Romania
Craiova, Dolj, Romania
Bucharest, Romania
Nove Zamky, Slovakia
Trbovlje, Slovenia
Chippenham, United Kingdom
Glasgow, United Kingdom
Letchworth, United Kingdom
Maidstone, United Kingdom
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials